Array BioPharma, Inc. (ARRY) Reports Top-Line Results from Phase 3 Study
Array BioPharma, Inc. (NASDAQ: ARRY) jointly announced with Pierre Fabre the results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162 (binimetinib), a MEK inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The study met its primary endpoint, meaningfully improving progression free survival (PFS) compared with vemurafenib, a BRAF inhibitor, alone. To view the full press release, visit: http://nnw.fm/iV5kO About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small…







